Title:
GLUCAGON ANALOGUE FOR TREATING METABOLIC DISEASES
Document Type and Number:
WIPO Patent Application WO/2019/101035
Kind Code:
A1
Abstract:
A glucagon analogue for treating metabolic diseases, the structure formula is as follows: H-X2-X3-GTFTSD-X10-SKYLD-X16-X17-AAQ-DFVQWLMN-X29-Xz or H-S-Q-GTFTSD-Y-SKYLD-X16-X17-AAQ-DFVQWLMN-X29-Xz-NH2. The described glucagon analogue has a GLP-1/GCG/GIP triple receptor agonist activity and better enzyme resistant stability for neutral endopeptidase (NEP) and dipeptidyl peptidase-4(DPP-4), and has a longer half-life in vivo and duration of action compared with natural glucagon, GLP-1 and GIP.
Inventors:
HUANG YANSHAN (CN)
Application Number:
PCT/CN2018/116166
Publication Date:
May 31, 2019
Filing Date:
November 19, 2018
Export Citation:
Assignee:
ZHEJIANG DOER BIOLOGICS CORP (CN)
International Classes:
C07K14/435; A61K38/00; A61P5/48; C12N5/10; C12N15/62; C12N15/85
Foreign References:
| CN104583233A | 2015-04-29 |
Other References:
GAULT, V.A.: "A novel GLP-1/glucagon hybrid peptide with triple-acting agonist activity at GIP, GLP-1 and glucagon receptors and therapeutic po- tential in high-fat fed mice", J. BIOL. CHEM., 28 October 2013 (2013-10-28), XP055337195
FINAN, B.: "A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents", NATURE MEDICINE, vol. 21, 8 December 2014 (2014-12-08), pages 1, XP002743282
TAI, J.J.: "Neuroprotective effects of a triple GLP-1/GIP/glucagon rece- ptor agonist in the APP/PS1 transgenic mouse model of Alzheimer' s disease", BRAIN RESEARCH, 16 October 2017 (2017-10-16), pages 1678, XP085299561
"GLP-1/GIP/Gcg", vol. 69, no. 2, 25 April 2017 (2017-04-25), pages 135 - 145
FOSGERAU, K.: "Peptide therapeutics: current status and future dire- ctions", DRUG DISCOVERY TODAY, vol. 20, 31 January 2015 (2015-01-31), pages 1, XP55614271
FINAN, B.: "A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents", NATURE MEDICINE, vol. 21, 8 December 2014 (2014-12-08), pages 1, XP002743282
TAI, J.J.: "Neuroprotective effects of a triple GLP-1/GIP/glucagon rece- ptor agonist in the APP/PS1 transgenic mouse model of Alzheimer' s disease", BRAIN RESEARCH, 16 October 2017 (2017-10-16), pages 1678, XP085299561
"GLP-1/GIP/Gcg", vol. 69, no. 2, 25 April 2017 (2017-04-25), pages 135 - 145
FOSGERAU, K.: "Peptide therapeutics: current status and future dire- ctions", DRUG DISCOVERY TODAY, vol. 20, 31 January 2015 (2015-01-31), pages 1, XP55614271
Attorney, Agent or Firm:
J.Z.M.C. PATENT AND TRADEMARK LAW OFFICE (GENERAL PARTNERSHIP) (CN)
Download PDF: